Dental Implants in Osteoporosis Patients
Yes, patients with osteoporosis can safely receive dental implants, and antiresorptive therapy (bisphosphonates or denosumab) does not need to be stopped prior to implant placement 1.
Key Evidence Base
The most recent International ONJ Taskforce consensus (2025) provides definitive guidance: dental implants may be safely placed in osteoporosis patients receiving antiresorptive therapy with no evidence of increased implant failure 1. Multiple systematic reviews confirm implant survival rates exceed 90% in osteoporotic patients, with no clinically significant differences in osseointegration compared to healthy individuals 2.
Pre-Operative Assessment
Bone Quality Evaluation
- Assess bone mineral density if not recently documented
- Evaluate local bone quality at implant site clinically and radiographically
- Consider trabecular bone score for enhanced fracture risk assessment 3
Medication History - Critical
Document the following antiresorptive therapy details:
- Type of medication: oral bisphosphonates (alendronate, risedronate), IV bisphosphonates (zoledronate), or denosumab
- Duration of therapy: Long-term bisphosphonate use (typically >3-4 years) carries marginally higher MRONJ risk
- Indication: Osteoporosis vs. malignancy (cancer patients have substantially higher MRONJ risk and require different management)
- Route: IV bisphosphonates carry higher risk than oral formulations 4
Risk Stratification for MRONJ
The absolute risk remains very low in osteoporosis patients: approximately 3 cases per 1000 patients on long-term bisphosphonates 1. This represents only a marginal increase over the general population baseline risk 5, 1.
Do NOT discontinue antiresorptive therapy before implant placement 1. The long half-life of bisphosphonates (years in bone) makes temporary discontinuation ineffective, while stopping denosumab risks rebound bone loss and fracture 5.
Peri-Operative Management
Antibiotic Prophylaxis - Strongly Recommended
Perioperative antimicrobial prophylaxis is strongly recommended for all patients on antiresorptive therapy undergoing implant placement 6. This represents a key preventive measure against MRONJ development, as inflammatory processes trigger osteonecrosis 6.
Surgical Technique Modifications
- Minimize surgical trauma: Use atraumatic technique with copious irrigation
- Avoid bone augmentation procedures when possible - these increase MRONJ risk 6
- Ensure primary soft tissue closure
- Remove mobile bone sequestra without exposing uninvolved bone 5
Vitamin D and Calcium
Ensure adequate vitamin D and calcium supplementation in all patients over 65 years with osteoporosis 3. This supports both skeletal health and optimal bone healing.
Post-Operative Monitoring
Follow-Up Protocol
- Monitor healing at regular intervals (every 8 weeks initially if any concerns) 5
- Assess for signs of MRONJ: exposed bone, non-healing wounds, pain, swelling, or infection
- Continue routine dental hygiene and professional maintenance
- Maintain communication between dental specialist and prescribing physician regarding lesion status if complications arise 5
MRONJ Staging and Management
If MRONJ develops (rare), treatment is stage-dependent 5:
- Stage 1 (exposed bone, asymptomatic): Antibacterial rinse, close monitoring
- Stage 2 (infection present): Oral antibiotics, pain control, limited debridement
- Stage 3 (extensive involvement): Surgical debridement/resection, systemic antibiotics
Critical Caveats
Denosumab-specific consideration: While the 2021 systematic review suggested negligible MRONJ risk with denosumab for osteoporosis 4, the 2025 Taskforce review indicates similar safety profiles for both bisphosphonates and denosumab in this population 1. Denosumab's shorter half-life means discontinuation carries significant rebound fracture risk and should be avoided 5.
Informed consent is mandatory: All patients on antiresorptive therapy must receive written information about MRONJ risk and provide informed consent before implant placement 6, 7. Document this thoroughly.
Osteoporosis itself is NOT a contraindication: The disease process does not prevent osseointegration or compromise implant survival 7, 2. Treatment planning should proceed based on local bone quality and systemic health factors, not osteoporosis diagnosis alone.